ANNX vs BCRX
ANNX: Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical complement pathway. BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design.
Side-by-side fundamentals
| Metric | ANNX | BCRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.23 | $9.51 | |
| Market cap as of 2026-07-23 | $857M | $2.4B | |
| P/E as of 2026-07-23 | n/a | 9.20 | |
| PEG as of 2026-07-23 | -1.19 | -0.01 | ANNX lower |
| Net margin as of 2026-07-23 | n/a | -51.7% | |
| Gross margin as of 2026-07-23 | n/a | +97.8% | |
| Operating margin as of 2026-07-23 | n/a | -45.1% | |
| ROE as of 2026-07-23 | -101.2% | -328.8% | ANNX higher |
| ROA as of 2026-07-23 | -76.0% | -97.3% | ANNX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 2.26 | ANNX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +75.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +22.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.18 | 0.57 | |
| 1-year return as of 2026-07-22 close | +118.2% | +9.9% | ANNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.